Corcept Therapeutics Incorporated is the subject of an ongoing securities class action lawsuit alleging material non-disclosure regarding its primary drug candidate relacorilant. The litigation was triggered after the FDA issued a Complete Response Letter on December 31, 2025, which rejected the company's application for the therapeutic. Following the regulatory decision, Corcept's stock price declined 50.4% in a single trading session, resulting in significant shareholder losses.
Investors who sustained losses exceeding $100,000 related to their Corcept holdings are being notified of an April 21, 2026 deadline to submit lead plaintiff applications in the class action proceeding. Lead plaintiff status provides investors with the ability to represent the class and influence litigation strategy, including settlement negotiations and fee arrangements with counsel.
The case centers on whether Corcept failed to adequately communicate information about relacorilant's development status or regulatory pathway prior to the FDA's rejection. Shareholders considering participation in the litigation are advised to consult with legal counsel regarding their eligibility and the implications of lead plaintiff designation.